Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Patent
1996-09-11
1998-11-10
Kishore, Gollamudi S.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
4241881, 424812, 436829, A61K 9127
Patent
active
058340157
ABSTRACT:
A protein-lipid vesicle that can be used to make an autogenous vaccine comprises patient-specific antigen, adjuvant or immunomodulator, and lipid carrier. In addition, a negatively charged lipid component is desirably included. The autogenous vaccine is useful to treat individuals with chronic diseases, including chronic infectious diseases and neoplasias. The chronic infectious diseases that can be treated include disease caused by infection with human immunodeficiency viruses.
REFERENCES:
patent: 5026557 (1991-06-01), Estis
patent: 5409698 (1995-04-01), Anderson
Krowka J. Immunol. 144, #7, p. 253,5 Apr. 1990.
Wassely Immuno Method 4, p. 217 1994.
J. Oleske et al, Autogenous Vaccine in the Treatment of Laryngeal Papilloma, Current Chemotherapy & Immunotherapy, Proc. 12th Intl. Cong. of Chemotherapy, Florence, Italy 19-24 Jul. 1981, pp. 1099-1101.
J. Oleske et al, Juvenile Papilloma of the Larynx, American Journal of Diseases of Children, vol. 121, May 1971, pp. 417-417.
Charlotte R. Kensil et al, Structure/Function Relationship in Adjuvants from Quillaja saponaria Molina, Vaccines 92. Cold Spring Harbor Laboratory Press, 1992, pp. 35-40.
Charlotte R. Kensil, et al, The Use of Stimulon Adjuvant to Boose Vaccine Response, Vaccine Research, vol. 2, No. 4, 1993, pp. 273-281
Mark J. Newman et al, Immunogenicity and Toxicity Testing of an Experimental HIV-1 Vaccine in Nonhuman Primates, AIDS Research and Human Retroviruses, vol. 8, No. 8, 1992, pp. 1413-1418.
Jia-Yan Wu et al, Accessory Cell Requirements for Saponin Adjuvant-Induced Class I MHC Antigen-Restricted Cytotoxic T-Lymphocytes, Cellular Immunology, vol. 154, pp. 393-406 (1994).
Jia-Yan Wu et al, Saponin Adjuvant Enhancement of Antigen-Specific Immune Responses to an Experimental HIV-1 Vaccine, The Journal of Immunology, vol. 148, pp. 1519-1525, No. 5, Mar. 1, 1992.
Mark J. Newman et al, Saponin Adjuvant Induction of Ovalbumin-Specific CD8.sup.+ Cytotoxic T Lymphocyte Responses, The Journal of Immunolgy, vol. 148, pp. 2357-2362, No. 8, Apr. 15, 1992.
Charlotte R. Kensil et al, Separation and Characterization of Saponins with Adjuvant Activity from Quillaja saponaria Molina Cortex, The Journal of Immunology, vol. 146, pp. 431-437, No. 2, Jan. 15, 1991.
Jonas E. Salk, M.D. with Mary Contakos et al, Use of Adjuvants in Studies on Influenza Immunization, J.A.M.A., vol. 151, No. 14, pp. 1169-1175, Apr. 4, 1953.
Barney S. Graham et al, Augmentation of Human Immunodeficiency Virus Type 1 Neutralizing Antibody by Printing with gp160 Recombinant Vaccinia and Boosting with rgp160 in Vaccinia-Naive Adults, The Journal of Infectious Diseases, 1993, vol. 167, pp. 533-537.
E. Celis et al, Regulation of the Human Immune Response to HBsAg: Effects of Antibodies and Antigen Conformation in the Stimulation of Helper T Cells by HBsAg, Hepatology, vol. 5, 744-751, 1985.
Jonas Salk, Prospects for the Control of AIDS by Immunizing Seropositive Individuals, Nature, vol. 327, Jun. 1987, pp. 473-476.
Emil Bisaccia et al, Extracorporeal Photopheresis in the Treatment of AIDS-Related Complex: A Pilot Study, Annals of Internal Medicine, vol. 113, No. 4, Aug. 15, 1990, pp. 270-275.
Antonio Lanzavecchia et al, T Cells Can Present Antigens Such As HIV gp120 Targeted to Their Own Surface Molecules, Nature, vol. 334, No. 11, Aug. 11, 1988, pp. 530-534.
J.S. McDougal et al, Antibody Response to Human Immunodeficiency Virus in Homosexual Men, The Journal of Clinical Investigation, Inc., vol. 80, Aug. 1987, pp. 316-324.
Robert B. Belshe et al, Safety and Immunogenicity of a Fully Glycosylated Recombinant gp160 Human Immunodeficiency Virus Type 1 Vaccine in Subjects at Low Risk of Infection, The Journal of Infectious Diseases, vol. 168, pp. 1387-1395, 1993.
Bruce D. Walker et al, HIV-specific Cytotoxic T Lymphocytes in Seropositive Individuals, Nature, vol. 328, Jul. 23, 1987, pp. 345-348.
Patricia E. Stanhope et al, Human CD4.sup.30 Cytolytic T Lymphocyte Responses to a Human Immunodeficiency Virus Type 1 gp160 Subunit Vaccine, The Journal of Infectious Diseases, vol. 168, pp. 92-100, Jul. 1993.
Alberto Beretta et al, HIV env Glycoprotein Shares a Cross-Reacting Epitope With a Surface Protein Present on Activated Human Monocytes and Involved in Antigen Presentation, Eur. J. Immunol., vol. 17 pp. 1793-1798, 1987.
Hana Golding et al, Common Epitope in Human Immunodeficiency Virus (HIV) I-GP41 and HLA Class II Elicits Immunosuppressive Autoantibodies Capable of Contributing to Immune Dysfunction in HIV I-infected Individuals, The Journal of Clinical Investigation, Inc., vol. 83, pp. 1431-1435, Apr. 1989.
Claudio De Santis et al, Cross-Reactive Response to Human Immunodeficiency Virus Type 1 (HIV-1) gp120 and HLA Class I Heavy Chains Induced by Receipt of HIV-1 Derived Envelope Vaccines, The Journal of Infectious Diseases, vol. 168, pp. 1396-1403, 1993.
David C. Redfield et al, Psoralen Inactivation of Influenza and Herpes Simplex Viruses and of Virus-Infected Cells, Infection and Immunity, vol. 32, pp. 1216-1226, Jun. 1981.
Philip O. Livingston, Approaches to Augmenting the IgG Antibody Response to Melanoma Ganglioside Vaccines, Annals New York Academy of Sciences, pp. 204-213.
David Gold et al, Viagene Begins New Gene Therapy Trial, Treatment Issues, vol. 8, No. 4, pp. 5-13.
Timothy L. Darrow, Ph.D., et al Immunotherapy of Human Melanoma with Gene-Modified Tumor Cell Vaccines Cancel Control, pp. 415-428, Sep./Oct. 1995.
Simon Wain-Hobson, Virological Mayhem, News and Views.
Gail Goodman-Snitkoff et al, Role of Intrastructural/Intermolecular Help in Immunization with Peptide-Phospholipid Complexes, The Journal of Immunology, vol. 147, pp. 410-415, Jul. 15, 1991.
M.G. Bernengo et al, The In Vitro Effect of a Calf Thymus Extract on the Peripheral Blood Lymphocytes of Patients with Warts, British Journal of Dermatology, vol. 102, pp. 11-16, 1980.
Snorri Ingimarsson et al, Side Effects of Long-Term Treatment with Human Leukocyte Interferon The Journal of Infectious Diseases, vol. 140, No. 4, pp. 560-563, Oct. 1979.
G.M. Scott et al, Effect of Injections of Small Doses of Human Fibroblast Interferon Into Genital Warts, British Journal of Venereal Diseases, vol. 55, pp. 422-445, 1979.
Sean Soltysik et al, Adjuvant Activity of QS-21 Isomers, Annals of the New York Academy of Sciences, vol. 690, pp. 392-295, Aug. 12, 1993.
A.C. White et al, A Purified Saponin Acts As An Adjuvant For a T-Independent Antigen, Immunobiology of Proteins and Peptides VI, pp. 207-210, 1991.
Charlotte R. Kensil et al, Novel Adjuvants from Quillaja saponaria Molina, AIDS Research Review, vol. 3, pp. 379-389, 1993.
J. Van Damme et al, Simultaneous Production of Interleukin 6, Interferon-Beta and Colony-Stimulating Activity by Fibroblasts After Viral and Bacterial Infection, Eur J Immunol vol. 19; pp. 163-168 (1989).
P.B. Sehgal et al, Regulation of the Acute Phase and Immune Responses in Viral Disease. Enhanced Expression of the Beta 2-Interferon/Hepatoxyte-Stimulating Factor/Interleukin 6 Gene in Virus-Infected Human Fibroblasts, J. Exp Med. vol. 167; pp. 1951-1956 (1988).
R.D. Garman et al, Characterization of Helper Factors Distinct from Interleukin 2 Necessary for the Generation of Allospecific Cytolytic T Lymphocytes, J. Immunol, vol. 130; pp. 756-762 (1983).
N.J. Roberts, Different Effects of Influenza Virus, Respiratory Syncytial Virus, and Sendai Virus on Human Lymphocytes and Macrophages, Infect Immun, vol. 35; pp. 1142-1146 (1982).
A. Prujansky-Jakobovits et al, Alteration of Lumphocyte Surface Properties by Insertion of Foreign Functional Components of Plasma Membrane, Proc Natl Acad Sci USA, vol. 77; pp. 7247-7251 (1980).
K. Leung et al, Selective Suppression of the Cytotoxic T Cell Response to Influenza Virus in Mice, Eur J. Immunol, vol. 10; pp. 803-810 (1980).
Y. Fukami et al, Difference in Capacity of Sendai Virus Envelope Components to Induce Cytotoxic T Lymphocytes in Primary and Secondary Immune Response, Infect Immun, vol. 26; pp. 815-821 (1979).
K. Megyeri et al, Stimulation of Interferon and Cytokine Gene Expression by Imiquimod and Stimulation by Sendai Virus Utilize S
Denny Thomas N.
Feketeova Eleonora
Gould-Fogerite Susan
Mannino Raphael J.
Oleske James M.
Albany Medical College
Kishore Gollamudi S.
University of Medicine and Dentistry of New Jersey
LandOfFree
Protein-lipid vesicles and autogenous vaccine comprising the sam does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protein-lipid vesicles and autogenous vaccine comprising the sam, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protein-lipid vesicles and autogenous vaccine comprising the sam will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1514261